Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-hypertension-2

Blood Pressure

Volumn 13, Issue 3, 2004, Pages 137-141

  Ekbom, Tord ^a   Linjer, Erland ^b   Hedner, Thomas ^b   Lanke, Jan ^c   De Faire, Ulf ^d   Wester, P O ^e   Dahlöf, Björn ^b   Scherstén, Bengt ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

Elderly; Hypertension; Myocardial infarction; STOP 2; Stroke

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; ISRADIPINE; LISINOPRIL; METOPROLOL; PINDOLOL;

AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; ELDERLY CARE; FATALITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 3242800667     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050410014944     Document Type: Article

References (24)

1. Himmelmann A, Hedner T, Hansson L, O'Donnell CJ, Levy D. Isolated systolic hypertension: an important cardiovascular risk factor. Blood Press 1998; 7: 197-207.
2. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352: 1801-7.
3. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64.
5. Lew EA. High blood pressure, other risk factors and longevity: the insurance viewpoint. Am J Med 1973; 55: 281-94.
6. O'Donell CJ, Ridker PM, Glynn RJ, et al. Hypertension and borderline isolated systolic hypertension increase the risks of cardiovascular disease and mortality in male physicians. Circulation 1997; 95: 1132-7.
7. Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10: 190-2.
8. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.
9. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
10. Staessen JA, Fagard R, Thijs L, et al. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
11. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-9.
12. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
13. Dahlöf B, Hansson L, Lindholm LH, et al. STOP-Hypertension-2: a prospective intervention trial of " newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension. Blood Press 1993; 2: 136-41.
14. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) study: A novel design for intervention trials. Blood Press 1992; 1: 113-19.
15. 1999 World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension. Blood Press 1999; 8 Suppl 1: S6-43.
16. Petrovitch H, Curb JD, Bloom-Marcus E. Isolated systolic hypertension and risk of stroke in Japanese-American men. Stroke 1995; 26: 25-9.
17. Nielsen WB, Vestbo J, Jensen GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens 1995; 9: 175-80.
18. Mancia G, Seravalle G, Grassi G. Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002; 20 Suppl 5: S21-7.
19. Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996; 39: 1646-54.
20. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
21. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-16.
22. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A for the CAPPP study group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention. Project Diabetes Care 2001; 24: 2091-6.
23. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New Engl J Med 2003; 348: 583-92.
24. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.